Martin Vazquez Sells 19,500 Shares of Outset Medical, Inc. (NASDAQ:OM) Stock

Posted by Defense World Staff on Mar 4th, 2023

Outset Medical, Inc. (NASDAQ:OM – Get Rating) COO Martin Vazquez sold 19,500 shares of the business’s stock in a transaction that occurred on Thursday, February 2nd. The stock was sold at an average price of $30.00, for a total value of $585,000.00. Following the completion of the sale, the chief operating officer now owns 104,435 shares of the company’s stock, valued at approximately $3,133,050. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Martin Vazquez also recently made the following trade(s):

On Wednesday, March 1st, Martin Vazquez sold 5,000 shares of Outset Medical stock. The stock was sold at an average price of $22.33, for a total value of $111,650.00.
On Thursday, February 16th, Martin Vazquez sold 1,931 shares of Outset Medical stock. The stock was sold at an average price of $24.36, for a total value of $47,039.16.
On Friday, January 27th, Martin Vazquez sold 4,674 shares of Outset Medical stock. The stock was sold at an average price of $27.92, for a total value of $130,498.08.
On Tuesday, January 3rd, Martin Vazquez sold 5,000 shares of Outset Medical stock. The stock was sold at an average price of $26.14, for a total value of $130,700.00.

Outset Medical Trading Up 7.4 %

Shares of NASDAQ:OM opened at $23.42 on Friday. The company has a market cap of $1.14 billion, a P/E ratio of -6.87 and a beta of 1.56. The company has a debt-to-equity ratio of 0.39, a current ratio of 7.19 and a quick ratio of 6.20. Outset Medical, Inc. has a 1 year low of $11.41 and a 1 year high of $48.71. The stock’s fifty day moving average price is $26.28 and its 200-day moving average price is $21.00.

Outset Medical (NASDAQ:OM – Get Rating) last posted its quarterly earnings data on Monday, February 13th. The company reported ($0.86) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.02. The company had revenue of $32.01 million during the quarter, compared to analysts’ expectations of $31.51 million. Outset Medical had a negative return on equity of 55.22% and a negative net margin of 141.24%. During the same quarter in the prior year, the business earned ($0.87) earnings per share. Sell-side analysts expect that Outset Medical, Inc. will post -3.6 earnings per share for the current year.

Institutional Trading of Outset Medical

A number of hedge funds have recently bought and sold shares of the company. Arizona State Retirement System increased its position in Outset Medical by 4.3% in the fourth quarter. Arizona State Retirement System now owns 11,514 shares of the company’s stock worth $297,000 after buying an additional 474 shares in the last quarter. Legal & General Group Plc increased its position in Outset Medical by 3.1% in the fourth quarter. Legal & General Group Plc now owns 18,425 shares of the company’s stock worth $476,000 after buying an additional 551 shares in the last quarter. Signaturefd LLC increased its position in Outset Medical by 84.8% in the fourth quarter. Signaturefd LLC now owns 1,641 shares of the company’s stock worth $42,000 after buying an additional 753 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Outset Medical by 38.4% during the third quarter. Tower Research Capital LLC TRC now owns 3,016 shares of the company’s stock worth $48,000 after purchasing an additional 837 shares in the last quarter. Finally, Assetmark Inc. grew its position in shares of Outset Medical by 49.7% during the third quarter. Assetmark Inc. now owns 2,712 shares of the company’s stock worth $43,000 after purchasing an additional 900 shares in the last quarter. Hedge funds and other institutional investors own 98.84% of the company’s stock.

Analyst Upgrades and Downgrades

OM has been the topic of several research analyst reports. The Goldman Sachs Group reduced their target price on Outset Medical from $34.00 to $29.00 and set a “buy” rating on the stock in a research note on Wednesday, November 9th. Royal Bank of Canada started coverage on Outset Medical in a research report on Friday, November 11th. They set an “outperform” rating and a $23.00 price target on the stock. Cowen dropped their price target on Outset Medical from $33.00 to $22.00 in a research report on Wednesday, November 9th. Morgan Stanley lifted their price target on Outset Medical from $17.00 to $27.00 and gave the company an “equal weight” rating in a research report on Friday, January 6th. Finally, Cowen dropped their price target on Outset Medical to $22.00 in a research report on Tuesday, November 15th.

About Outset Medical

(Get Rating)

Outset Medical, Inc, a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings.